Research Partnership Publishes a New Patient Living with Diabetes (LATAM) 2018 Report and New Reports Scheduled for 2019
Living with Diabetes LATAM is a report based on a new study conducted amongst approximately 116 Type 2 (T2D) diabetes patients in Brazil and 105 patients in Mexico. The study comprised of 30-minute quantitative online and qualitative telephone interviews with T2D patients.
The LATAM report is intended to help pharmaceutical companies developing products in diabetes in this region to gain a deeper understanding of how patients come to be diagnosed with it and how it impacts their day-to-day lives physically, emotionally and socially. It also explores patient attitudes and perceptions towards treatment, the healthcare professionals managing their condition, as well as identifying the types of support and education patients need at key stages of their journey.
Head of Living With, Mariel Metcalfe commented, “With an increase in prevalence to 14% of the population in Mexico and 9% of the population in Brazil, diabetes is now one of the leading causes of mortality and disability in Latin America. This report provides comprehensive, quantitative insights into patient behaviours, perceptions and needs, as well as their feelings at key stages of their journey living with Type 2 Diabetes.”
Currently being conducted in LATAM but looking to expand the survey to the US, EU and Asia, Living with Diabetes is just one in a series of reports offering comprehensive insight into the chronic disease patient journey from pre-diagnosis to stabilisation. The Living with Atopic Dermatitis (US), Crohn’s (EU & US), Lupus- SLE (EU & US), Non-alcoholic Steatohepatitis - NASH (US), Rheumatoid Arthritis (US), Psoriasis (EU), Psoriatic arthritis - PsA (EU) and Ulcerative Colitis (EU & US) reports are published and available to purchase.
Living with AS (US & US), Rheumatoid Arthritis (EU & Japan) and Non-alcoholic Steatohepatitis - NASH (EU) reports will be launched in the 1st quarter of 2019.
Visit www.researchpartnership.com/livingwith for more information.
More detailed findings from the study can be provided from Mariel Metcalfe on marielm@researchpartnership.com
Media Contact:
Mariel Metcalfe,
Head of Living with,
marielm@researchpartnership.com,
T: +44 7584 625 836
Julie Denny,
Marketing Director,
julied@researchpartnership.com,
T: +44 20 8069 5006
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
